Palisade Bio (NASDAQ:PALI) Issues Quarterly Earnings Results, Beats Estimates By $1.10 EPS

Key Points

• Palisade Bio beat expectations, reporting $1.08 EPS vs. consensus of ($0.02) (a $1.10 beat), yet the stock fell about 5% to $1.89 on the trading day.
• Analyst coverage is mixed but generally positive, with recent initiations including Piper Sandler ($25 target) and B. Riley ($7 target); the MarketBeat consensus rating is a “Moderate Buy” with a $12.33 target.
• Palisade is a clinical‑stage biotech focused on a TLR9 prodrug (lead candidate PDS0108 in Phase 1/2), with a market cap around $282 million and institutional ownership of roughly 11.8%.

Palisade Bio (NASDAQ:PALI - Get Free Report) posted its earnings results on Friday. The company reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.02) by $1.10, FiscalAI reports.

Palisade Bio Stock Down 5.0%

Shares of NASDAQ:PALI traded down $0.10 during trading on Friday, reaching $1.89. The stock had a trading volume of 2,899,494 shares, compared to its average volume of 4,242,333. The stock has a fifty day simple moving average of $1.77 and a two-hundred day simple moving average of $1.69. Palisade Bio has a 52 week low of $0.53 and a 52 week high of $2.64. The firm has a market capitalization of $281.61 million, a price-to-earnings ratio of -0.89 and a beta of 1.53.

Analyst Ratings Changes

Several brokerages have recently commented on PALI. B. Riley Financial assumed coverage on shares of Palisade Bio in a research note on Friday, January 9th. They set a "buy" rating and a $7.00 price target on the stock. Piper Sandler initiated coverage on shares of Palisade Bio in a report on Monday, December 29th. They issued an "overweight" rating and a $25.00 price objective for the company. Weiss Ratings reissued a "sell (e+)" rating on shares of Palisade Bio in a research report on Thursday, January 22nd. Clear Str upgraded Palisade Bio to a "strong-buy" rating in a report on Monday, December 29th. Finally, Stifel Nicolaus began coverage on Palisade Bio in a research report on Wednesday, February 25th. They issued a "buy" rating and a $5.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $12.33.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Cetera Investment Advisers bought a new position in shares of Palisade Bio in the fourth quarter worth about $25,000. Schonfeld Strategic Advisors LLC bought a new stake in Palisade Bio during the 4th quarter valued at approximately $26,000. Virtu Financial LLC bought a new position in Palisade Bio in the 4th quarter worth approximately $28,000. Atom Investors LP bought a new stake in shares of Palisade Bio in the fourth quarter valued at approximately $33,000. Finally, WINTON GROUP Ltd bought a new position in Palisade Bio during the fourth quarter worth $35,000. Institutional investors own 11.79% of the company's stock.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.